Bio Spectrum August 2017

COVERSTORY ............................................................................................... 20

Shortage in Europe of

ONCOLOGY DRUGS

...an opportunity for

INDIAN PHARMA?

COVER

DESIGN BY:

thirdconcept design

BIOANALYSIS

32

Industry needs to work closely with

Indian govt for smooth implementation of GST

37

India free from Avian Influenza

(^6) BIOContent BioSpectrum | August 2017 | http://www.biospectrumindia.com
Indian drug companies are facing strong headwinds due
to prompt regulatory action of United States Food and
Drug Administration (USFDA), likely imposition of Border
Adjustment Tax (BAT) and delay in new drug approvals.
Probably, it is the best time for Indian pharma companies to
explore opportunities and business in the European market.
BIOSPECIAL
26
US FDA Warning
letters and
Indian pharma...